Boston Scientific Acquires Bolt Medical for Up to $900M: Intravascular Lithotripsy, IVL Competitive Dynamics with J&J Shockwave, and the $3.8B Calcified Artery Device Market

Deal at a Glance

On January 8, 2025, Boston Scientific Corporation (NYSE: BSX) announced a definitive agreement to acquire Bolt Medical, Inc., a privately held medical device company based in Carlsbad, California, developing a laser-based intravascular lithotripsy (IVL) platform for the treatment of coronary and peripheral artery disease. The transaction closed on April 3, 2025, following FDA 510(k) clearance of Bolt Medical's IVL system for peripheral above-the-knee indications.

This acquisition is the opening salvo in what has become the most competitive new segment in interventional cardiology: the intravascular lithotripsy platform wars. With J&J's $13.1 billion acquisition of Shockwave Medical completed in May 2024, Boston Scientific's Bolt Medical deal, Abbott's announced entry into IVL, and Stryker's acquisition of Amplitude Vascular Systems, the battle to treat calcified arterial plaque is reshaping the cardiovascular device landscape.

Deal Structure and Timeline

Boston Scientific structured the Bolt Medical acquisition as an all-cash transaction with two components: $600 million in upfront consideration on a 100% ownership basis, and up to approximately $300 million in additional milestone payments tied to regulatory achievements. Because Boston Scientific already held approximately 26% of Bolt Medical as a strategic investor since 2019, the net cash outflow at closing was significantly lower than the headline figure.

The deal timeline moved quickly:

• 2019: Boston Scientific makes initial strategic investment in Bolt Medical, acquiring ~26% equity stake
• April 2024: Bolt Medical completes enrollment in the RESTORE ATK pivotal trial (95 patients, 11 European centers)
• December 2024: Bolt Medical receives FDA approval to commence the FRACTURE IDE clinical trial for coronary indications
• January 8, 2025: Boston Scientific announces definitive acquisition agreement
• January 24, 2025: Bolt Medical submits 510(k) premarket notification to FDA (K250225)
• March 25, 2025: FDA issues 510(k) clearance letter for peripheral ATK indication
• April 3, 2025: Boston Scientific closes the acquisition
• July 2025: FRACTURE coronary IDE trial begins US enrollment (400 patients, 30 centers)
• May 11, 2026: RESTORE first-in-human coronary study published in Circulation: Cardiovascular Interventions with positive results

Why Boston Scientific Paid a Premium for Bolt

The $600 million upfront payment for a company with no commercial revenue at the time of acquisition reflects the strategic importance of the IVL segment. Boston Scientific had watched J&J acquire Shockwave Medical for $13.1 billion in 2024, creating a dominant position in one of the fastest-growing segments of interventional cardiology. By acquiring Bolt Medical — a company it already knew intimately through a six-year investment relationship — Boston Scientific secured a differentiated IVL platform with both peripheral and coronary potential at a fraction of what J&J paid for Shockwave.

The deal also follows a pattern for Boston Scientific: identify promising early-stage technology through strategic investments, then acquire outright once clinical validation and regulatory progress de-risk the asset. The company used a similar playbook with its acquisition of Farapulse for pulsed field ablation and with its investment in and subsequent acquisition of other cardiovascular technologies.

Bolt IVL Technology Deep Dive

The Clinical Problem: Calcified Arterial Disease

Cardiovascular disease remains the leading cause of death globally. A significant subset of patients with coronary artery disease (CAD) and peripheral artery disease (PAD) develop severe arterial calcification — deposits of calcium phosphate that harden and stiffen the arterial wall. These calcified lesions present a major challenge during percutaneous interventions: they resist balloon dilatation, cause stent underexpansion, increase the risk of procedural complications (dissection, perforation, abrupt closure), and are associated with higher rates of restenosis and target lesion failure.

Traditional treatment options for calcified lesions — including high-pressure balloon angioplasty, cutting/scoring balloons, and atherectomy (rotational, orbital, or laser) — have significant limitations in efficacy and safety. Intravascular lithotripsy was developed to address this gap by delivering sonic pressure waves that selectively fracture calcium while sparing soft tissue.

How the Bolt IVL System Works

The Bolt IVL system uses a fundamentally different energy source than Shockwave's electrohydraulic platform. Bolt Medical's approach is laser- and optics-based: a fiber-optic delivery system inside a balloon catheter generates acoustic pressure waves through rapid laser-induced vaporization of the surrounding fluid. The key technical features include:

• Laser-generated acoustic pressure waves: A pulsed laser creates rapid vapor bubbles in the contrast-filled balloon, generating controlled acoustic pressure waves that propagate through the fluid medium to interact with calcium in the vessel wall
• Visible, directional emitters: The system incorporates visible light emitters that allow the physician to confirm energy delivery direction, providing a degree of control not available in omnidirectional systems
• Low-pressure balloon dilatation: After lithotripsy treatment, the same balloon is inflated at low pressure to dilate the vessel, combining calcium modification with angioplasty in a single device
• Balloon catheter format: The system is delivered through standard percutaneous access and is compatible with conventional interventional techniques

The device was cleared by FDA through the 510(k) pathway with the Shockwave Medical Intravascular Lithoplasty System (K203365, cleared April 22, 2021) as the predicate device. The FDA found the Bolt IVL system to be substantially equivalent to the predicate for the peripheral indication.

Bolt IVL vs. Shockwave IVL: Technology Comparison

The directional emitter design is the most significant differentiator. While Shockwave's emitters deliver energy circumferentially around the balloon, Bolt's directional emitters allow the physician to target calcium more precisely, potentially reducing energy delivery to non-calcified tissue segments. Whether this translates into clinically meaningful differences in outcomes remains to be seen and will likely be debated as head-to-head data emerges.

Clinical Evidence

RESTORE Pivotal Trials: Peripheral Artery Disease

Bolt Medical built its clinical evidence base through the RESTORE program — a series of European prospective, single-arm, multicenter trials:

RESTORE ATK (Above the Knee): Enrolled 95 patients across 11 European centers. Completed enrollment in April 2024. The study assessed the safety and efficacy of the Bolt IVL system for treating calcified lesions in the peripheral vasculature above the knee. Results were presented by Professor Thomas Zeller at VIVA24 (November 2024) and used to support both the FDA 510(k) submission and CE Mark application.

RESTORE BTK (Below the Knee): A parallel study evaluating the system for below-the-knee calcified lesions, an anatomically challenging subset where vessel diameter is smaller and the consequences of complications are more severe.

RESTORE Coronary First-In-Human Study

Published on May 11, 2026, in Circulation: Cardiovascular Interventions, the RESTORE coronary first-in-human study evaluated the Bolt IVL system for the treatment of severely calcified coronary stenoses during percutaneous coronary intervention. The study reported positive initial results, suggesting the laser-based platform may be effective for coronary calcium modification. The publication noted that much more research is still necessary, and a larger trial — FRACTURE — is already underway.

FRACTURE IDE Trial: Coronary Indication

The global FRACTURE trial is a prospective, nonrandomized, single-arm, multicenter interventional study designed to evaluate the safety and efficacy of the Bolt IVL system in patients undergoing PCI for severely calcified coronary lesions. Key parameters:

• Design: Prospective, nonrandomized, single-arm, multicenter
• Enrollment: Estimated 400 patients
• Sites: 30 centers in the United States and Europe
• FDA IDE Approval: December 2024
• First US Enrollment: July 2025 (Brian K. Jefferson, MD, TriStar Centennial Medical Center, Nashville)

The FRACTURE trial is critical for Boston Scientific because the coronary indication represents the significantly larger commercial opportunity within IVL. Coronary IVL procedures outnumber peripheral IVL procedures, and the coronary calcified lesion market is the primary driver of the segment's growth projections.

The Intravascular Lithotripsy Market

Market Size and Growth

The global IVL market is one of the fastest-growing segments in medical devices. According to iData Research's 2026 Global IVL Market Report:

• 2025 Market Size: Approximately $1.1 billion
• 2032 Projected Market Size: More than $3.8 billion
• Peripheral IVL Segment: $335 million in 2025, projected CAGR of 23.3% to $1.4 billion by 2032
• Coronary IVL Segment: $366 million in 2025, projected to $649 million by 2035

Other market research estimates vary in absolute numbers but consistently point to 12–16% CAGR growth through the early 2030s, driven by aging populations, increasing prevalence of calcified arterial disease, expanding clinical evidence, and improvements in reimbursement.

Competitive Landscape

Johnson & Johnson's Shockwave Medical remains the dominant player by a wide margin. J&J acquired Shockwave for $13.1 billion in May 2024, making it one of the largest medtech acquisitions in recent history. Shockwave generated approximately $730 million in revenue in 2023, and J&J has positioned it as a priority platform expected to generate at least $1 billion in annual sales. J&J MedTech's cardiovascular segment grew 15.8% to $8.9 billion in 2025, with Shockwave as a key growth driver.

In March 2025, Shockwave launched its Javelin Peripheral IVL Catheter in the US — a novel forward-emitting platform designed to both modify calcium and cross extremely narrow vessels. The company also presented data from 23 studies at EuroPCR 2025, including the EMPOWER CAD study confirming IVL benefits in female patients.

Regulatory Strategy and 510(k) Pathway

The Peripheral 510(k) Clearance

Bolt Medical pursued the 510(k) pathway for its peripheral indication, a strategy that enabled a faster time to market compared to a de novo or PMA pathway. The key regulatory milestones:

1. 510(k) submission (K250225): Submitted January 24, 2025, received by FDA January 27, 2025
2. Predicate device: Shockwave Medical Intravascular Lithoplasty System (K203365), cleared April 22, 2021
3. Indications for use: Lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature (iliac, femoral, iliofemoral, popliteal, and infra-popliteal arteries). Explicitly not for use in coronary, carotid, or cerebral vasculature.
4. Classification: Class II, Product Code PPN, Regulation 21 CFR 870.1250 (Percutaneous Catheter)
5. Clearance date: March 25, 2025

The 510(k) pathway was viable because the Bolt IVL system was determined to be substantially equivalent to the Shockwave predicate device in terms of intended use and technological characteristics, despite the different energy source (laser vs. electrohydraulic). The RESTORE ATK clinical data from Europe provided supporting evidence of safety and effectiveness.

The Coronary IDE Pathway

For the coronary indication, Bolt Medical / Boston Scientific is pursuing an Investigational Device Exemption (IDE) through the FRACTURE trial. This is the standard regulatory pathway for higher-risk coronary devices that require prospective clinical data to support a future marketing application. The 400-patient, 30-center global trial will generate the safety and efficacy data needed for a future FDA submission for the coronary indication.

The coronary pathway is longer and more expensive than the peripheral 510(k) route, but the commercial payoff is substantially larger. Coronary IVL represents the majority of the addressable market, and obtaining a coronary indication would position Boston Scientific to compete directly with Shockwave across all major IVL applications.

Strategic Implications

For Boston Scientific

The Bolt Medical acquisition gives Boston Scientific entry into the IVL segment — one of the few remaining high-growth cardiovascular device categories where BSX did not have a presence. The company's interventional cardiology portfolio already includes market-leading positions in structural heart (WATCHMAN), electrophysiology, and peripheral interventions. Adding IVL fills a gap and allows BSX to offer interventional cardiologists a more complete suite of calcium modification tools.

The key question for BSX is the timeline for the coronary indication. With the FRACTURE trial just beginning enrollment in mid-2025, coronary FDA clearance is likely several years away. In the interim, BSX can commercialize the peripheral indication and build clinical experience, but the major revenue opportunity remains the coronary space where Shockwave currently operates unchallenged.

For J&J / Shockwave

Boston Scientific's entry into IVL validates the market that Shockwave built but also introduces a well-capitalized competitor with an extensive interventional cardiology commercial infrastructure. The competitive dynamics will likely intensify as Abbott enters the market and clinical data accumulates for all platforms.

For the Broader Cardiovascular Device Market

The IVL platform wars illustrate a broader trend in cardiovascular medtech: large strategics acquiring innovative platforms to compete across the full spectrum of interventional procedures. As IVL becomes a standard of care for calcified lesions, the ability to offer IVL alongside stents, balloons, and other interventional tools will become a competitive differentiator in hospital purchasing decisions.

Frequently Asked Questions

What is intravascular lithotripsy (IVL)? IVL is a minimally invasive technique that uses sonic pressure waves delivered through a balloon catheter to fracture calcified plaque in arteries. The technology was adapted from urological lithotripsy (kidney stone treatment) and allows interventional physicians to modify calcium without the risks associated with atherectomy or high-pressure balloon dilatation.

How is Bolt Medical's IVL different from Shockwave's IVL? Bolt Medical uses a laser-optic energy source to generate acoustic pressure waves, while Shockwave uses electrohydraulic spark-gap emitters. Bolt's system also features directional emitters, allowing more targeted energy delivery, compared to Shockwave's circumferential emitters.

Is the Bolt IVL system FDA-approved for coronary use? No. As of May 2026, the Bolt IVL system is FDA-cleared only for peripheral above-the-knee indications. The FRACTURE IDE clinical trial is enrolling patients to generate data for a future coronary FDA submission.

How big is the IVL market? The global IVL market was approximately $1.1 billion in 2025 and is projected to exceed $3.8 billion by 2032, growing at a CAGR of approximately 15%.

Why did Boston Scientific acquire Bolt Medical? Boston Scientific acquired Bolt Medical to enter the fast-growing IVL segment, compete with J&J's Shockwave Medical, and expand its interventional cardiology portfolio. BSX had been a strategic investor in Bolt Medical since 2019 and had familiarity with the technology and team.

What other companies are developing IVL systems? Abbott has announced plans for an IVL clinical trial. Stryker acquired Amplitude Vascular Systems for peripheral IVL. Elixir Medical, FastWave Medical, and MicroPort (in China) are also developing IVL platforms.